within Pharmacolibrary.Drugs.ATC.V;

model V03AF05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0038333333333333336,
    adminDuration  = 600,
    adminMass      = 910 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.024,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.086,
    k12             = 120,
    k21             = 120
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AF05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amifostine is a cytoprotective adjuvant used to reduce the toxic side effects of chemotherapy and radiation therapy. It acts as a prodrug that is dephosphorylated by alkaline phosphatase to an active metabolite, which then protects normal (but not cancer) cells from DNA-damaging agents. It is approved for use to decrease xerostomia in radiation treatment for head and neck cancer, and to reduce cumulative renal toxicity with cisplatin use in advanced ovarian cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients receiving a standard intravenous infusion of amifostine prior to chemotherapy.</p><h4>References</h4><ol><li><p>Korst, AE, et al., &amp; van der Vijgh, WJ (1996). Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. <i>Cancer chemotherapy and pharmacology</i> 39(1-2) 162–166. DOI:<a href=\"https://doi.org/10.1007/s002800050553\">10.1007/s002800050553</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8995515/\">https://pubmed.ncbi.nlm.nih.gov/8995515</a></p></li><li><p>Cassatt, DR, et al., &amp; Bachy, CM (2002). Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. <i>Seminars in oncology</i> 29(6 Suppl 19) 2–8. DOI:<a href=\"https://doi.org/10.1053/sonc.2002.37355\">10.1053/sonc.2002.37355</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12577236/\">https://pubmed.ncbi.nlm.nih.gov/12577236</a></p></li><li><p>Zackrisson, AL, et al., &amp; Peterson, C (2002). No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. <i>European journal of clinical pharmacology</i> 58(2) 103–108. DOI:<a href=\"https://doi.org/10.1007/s00228-002-0434-9\">10.1007/s00228-002-0434-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12012141/\">https://pubmed.ncbi.nlm.nih.gov/12012141</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AF05;
